Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RNAi etc. |
| Sample | HCC tissues, cell lines (HepG2 etc.) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA ANRIL expression in HCC tissues was significantly higher than in the adjacent non-tumor tissues. The expression of lncRNA ANRIL was remarkably associated with the histologic grade and TNM stage of HCC patients. In addition, HCC patients with higher lncRNA ANRIL expression had significantly poorer overall survival. Moreover, in vitro assays revealed that the decreased expression of lncRNA ANRIL could suppress the cell proliferation, migration and invasion HCC cells. |
| Pubmed ID | 26045820 |
| Year | 2015 |
| Title | High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |